Kura Oncology, Inc. (KURA) Stock: Price, Forecast & Analyst Target
Kura Oncology, Inc. (KURA) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $7.34 (-2.00%), as of the Nov 18, 2026 trading session; market cap $674M.
Educational signal · not a buy or sell recommendation · How to read this
Kura Oncology, Inc. · KURA · NASDAQ
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for cancer treatment in the United States. Its pipeline features lead candidates ziftomenib for acute leukemias and tipifarnib for solid tumors and hematologic indications, including a collaboration with Novartis.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Kura Oncology (KURA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, stalling growth and an expensive valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 4 of the last 8 reports
- Altman Z -3.45 · Piotroski F 3
Holding back: weak fundamentals, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 13 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 12 | Weak | |
| 12 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.34 | |
| Change on the day | -2.00% | |
| 52-week range | $6.75 – $13.90 | |
| Market capitalisation | $674M | — |
| Shares traded on the day | 2.46M |
Price & events
Other perspectives
Council score for Kura Oncology (KURA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Kura Oncology (KURA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kura Oncology, Inc. (KURA) is listed on NASDAQ. It employs 260 people and is led by Troy Wilson. The market values it at $674M.
What do the latest results show for Kura Oncology (KURA)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $21M | -$74M | -$0.85 (diluted) |
| Q4 FY2025 | $17M | -$81M | -$0.92 (diluted) |
| Q1 FY2026 | $18M | -$73M | -$0.83 (diluted) |
| Q2 FY2026 | $21M | -$68M | -$0.77 (diluted) |
What are the financial strengths and risks for Kura Oncology (KURA)?
Short answer
What is holding it back is weak fundamentals, a rich price, soft growth. The distress and quality screens read Altman Z -3.45 · Piotroski F 3. Trailing ratios: ROA -32.2% · current ratio 3.60.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -3.45 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Kura Oncology (KURA)?
Short answer · as of
Current published price targets run low $24.00 · high $24.00 · consensus $24.00 · median $24.00 against a quoted price of $7.34 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Kura Oncology compare with its peers?
Short answer
Kura Oncology's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.06 Nov 18, 2026 | $1.40B | 76 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $40.06 Nov 18, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $1.10B | 66 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| Kura Oncology (KURA) — this page | $7.34 | $674M | 12 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $24.00 – $24.00
- Consensus target
- $24.00
- Median target
- $24.00
Consensus record · Captured .
Measured against a quoted price of $7.34 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held KURA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KURA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Kura Oncology (KURA)?
What Investors Ask About Kura Oncology (KURA)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for KURA?
KURA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is KURA a good stock to buy?
Stock Expert AI does not rate KURA buy, sell or hold. Kura Oncology, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KURA stock price today?
The last price recorded for Kura Oncology, Inc. (KURA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KURA price target?
The analyst consensus price target for Kura Oncology, Inc. (KURA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for KURA?
Kura Oncology, Inc. (KURA) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does KURA data refresh on this page?
KURA's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KURA's recent stock price performance?
Kura Oncology, Inc. (KURA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused pipeline of small molecule inhibitors for specific cancer targets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KURA overvalued or undervalued right now?
Kura Oncology, Inc. (KURA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of KURA?
Fractional-share availability for Kura Oncology, Inc. (KURA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com